Beijing Gene Plus Technology   Report issue

For profit Phase 2
Founded: Beijing China (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2017
NCT03190616
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Beijing gene plus technology co., LTD

Active Ingredients

Drugs in Phase 2 Trials (1)

lapatinib (tykerb) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1